The European Union Requires Public Disclosure of Clinical Trials for Clinical Animal Supplements (CAS)

The increasing global interest in companion animals and animal welfare has led to a rapid expansion of the market for Clinical Animal Supplements (CAS). Developed nations, particularly those within the European Union (EU), underscore the necessity for CAS to be specifically formulated to address the physiological characteristics and metabolic requirements of companion animals. To guarantee both safety and efficacy, it is required that clinical trials involving animals be conducted prior to the release of these products.

Clinical Animal Supplements (CAS) are subject to stringent regulations as outlined in Regulation (EU) 2017/625 and Regulation (EU) 767/2009, which differentiates them from dietary supplements intended for human consumption. Prominent organizations, including the European Pet Food Industry Federation (FEDIAF) and the European Food Safety Authority (EFSA), are responsible for establishing safety standards pertaining to the ingredients and additives used in these products. Furthermore, countries such as the United Kingdom, Australia, and Canada mandate the transparent disclosure of clinical trial data for Clinical Animal Supplements (CAS) to the public. This policy not only enhances the accessibility of information for pet owners but also strengthens consumer confidence in these products.

Such institutional frameworks are essential for significantly enhancing pet health. The global market for Clinical Animal Supplements (CAS) is experiencing continuous growth, supported by scientific evidence and transparency, and is increasingly recognized as a crucial resource for improving the quality of life for companion animals.